ASPP: A new family of oncogenes and tumour suppressor genes

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 196-200

  Sullivan, A ^a   Lu, X ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; ASPP; p53

Indexed keywords

ANTHRACYCLINE; APOPTOSIS STIMULATING PROTEIN P 53; BORTEZOMIB; DNA; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CODON; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE SILENCING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTO ONCOGENE; RHABDOMYOSARCOMA; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; WILD TYPE;

CARRIER PROTEINS; CODON; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; ONCOGENES; POLYMORPHISM, GENETIC;

EID: 33846551682     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603525     Document Type: Short Survey

References (40)

1. Agirre X, Roman-Gomez J, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, Vazquez I, Zalacain M, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prosper F (2006) ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 25: 1862-1870
2. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell A, Heath V, Tavassoli M, Farrell P, Smith P, Lu X, Crook T (2003a) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387-402
3. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X (2004) ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 24: 1341-1350
4. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X (2003b) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33: 162-167
5. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds the proline rich region of p53 and modulates the apoptotic function of codon 72 polymorphic p53. Nat Genet 38: 1133-1141
6. Cao Y, Hamada T, Matsui T, Date T, Iwabuchi K (2004) Hepatitis C virus core protein interacts with p53-binding protein, 53BP2/Bbp/ASPP2, and inhibits p53-mediated apoptosis. Biochem Biophys Res Commun 315: 788-795
7. Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD (2005) Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death Differ 12: 358-368
8. Chen Y, Liu W, Naumovski L, Neve RL (2003) ASPP2 inhibits APP-BP1-mediated NEDD8 conjugation to cullin-1 and decreases APP-BP1-induced cell proliferation and neuronal apoptosis. J Neurochem 85: 801-809
9. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S (2005) Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11: 8623-8631
10. Espanel X, Sudol M (2001) Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 276: 14514-14523
11. Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH, Lu X (2005) ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ 12: 369-376
12. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99: 937-942
13. Gorina S, Pavletich NP (1996) Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001-1005
14. Hershko T, Chaussepied M, Oren M, Ginsberg D (2005) Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ 12: 377-383
15. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328
16. Ju H, Lee KA, Yang M, Kim HJ, Kang CP, Sohn TS, Rhee JC, Kang C, Kim JW (2005) TP53BP2 locus is associated with gastric cancer susceptibility. Int J Cancer 117: 957-960
17. Lettre G, Kritikou EA, Jaeggi M, Calixto A, Fraser AG, Kamath RS, Ahringer J, Hengartner MO (2004) Genome-wide RNAi identifies p53-dependent and -independent regulators of germ cell apoptosis in C. elegans. Cell Death Differ 11: 1198-1203
18. Liu ZJ, Lu X, Zhang Y, Zhong S, Gu SZ, Zhang XB, Yang X, Xin HM (2005) Downregulated mRNA expression of ASPP and the hypermethylation of the 5′-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett 579: 1587-1590
19. Liu ZJ, Zhang Y, Zhang XB, Yang X (2004) Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia 18: 880
20. Lossos IS, Natkunam Y, Levy R, Lopez CD (2002) Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma 43: 2309-2317
21. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692
22. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K, Sekido Y (2004) p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 100: 1673-1682
23. Mori T, Okamoto H, Takahashi N, Ueda R, Okamoto T (2000) Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett 465: 124-128
24. Nakagawa H, Koyama K, Murata Y, Akiyama T, Nakamura Y (2000) APCL, a central nervous system-specific homologue of adenomatous polyposis coli tumour suppressor binds to 53-binding protein 2 and translocates it to the perinucleus. Cancer Res 60: 101-105
25. Naumovski L, Cleary ML (1996) The p53-binding protein 53BP2 also interacts with bcl2 and impedes cell cycle progression at G2/M. Mol Cell Biol 16: 3884-3892
26. Ohno A, Hirashima T, Kubo A, Masuda N, Takada M, Fujiwara H, Yasumitsu T, Kiku M, Fukuoka M, Nakagawa K (1997) p53 status and prognosis in stage I-IIIa non-small cell lung cancer. Int J Oncol 10: 521-528
27. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A (2005) Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 23: 7043-7049
28. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH (1996) Specific loss of apoptotic but not cell-cycle arrest function in a human tumour derived p53 mutant. EMBO 15: 827-838
29. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781-794
30. Sarraf SA, Stancheva I (2004) Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell 15: 595-605
31. Sgroi DC, Teng S, Robinson G, Le Vangie R, Hudson JR, Elkahloun AG (1999) In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 59: 5656-5661
32. Sjalander A, Birgander R, Kivela A, Beckman G (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45: 144-149
33. Stanelle J, Stiewe T, Theseling CC, Peter M, Putzer BM (2002) Gene expression changes in response to E2F1 activation. Nucleic Acids Res 30: 1859-1867
34. Takahashi N, Kobayashi S, Kajino S, Imai K, Tomoda K, Shimizu S, Okamoto T (2005) Inhibition of the 53BP2S-mediated apoptosis by nuclear factor kappaB and Bcl-2 family proteins. Genes Cells 10: 803-811
35. Thornton JK, Dalgleish C, Venables JP, Sergeant KA, Ehrmann IE, Lu X, Saunders PT, Elliott DJ (2006) The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo. Oncogene 25: 3104-3112
36. Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R, Lu X (2006) ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 20: 1262-1267
37. Yang J-P, Hori M, Sanda T, Okamoto T (1999a) Identification of a novel inhibitor of nuclear factor-κB, RelA-associated inhibitor. J Biol Chem 274: 15662-15670
38. Yang J-P, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T (1999b) NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18: 5177-5186
39. Zhang X, Wang M, Zhou C, Chen S, Wang J (2005) The expression of iASPP in acute leukemias. Leuk Res 29: 179-183
40. Zhu Z, Ramos J, Kampa K, Adimoolam S, Sirisawad M, Yu Z, Chen D, Naumovski L, Lopez CD (2005) Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. J Biol Chem 280: 34473-34480